Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Association of Benzodiazepines and Antidepressants With 180-Day Mortality Among Patients With Dementia Receiving Antipsychotic Pharmacotherapy: A Nationwide Registry-Based Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Six generations of CHMP2B-mediated Frontotemporal Dementia: Clinical features, predictive testing, progression, and survival

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of antipsychotics on mortality risk in patients with dementia with and without comorbidities

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A personalized dementia care intervention for family carers from minority ethnic groups in Denmark: A pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Feasibility of a culturally tailored dementia information program for minority ethnic communities in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Hospital readmissions following infections in dementia: a nationwide and registry-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Antipsychotic drugs are known to increase mortality among patients with dementia. Many patients receive concomitant treatment with other psychotropic agents. The aim of this retrospective cohort study was to investigate the impact of benzodiazepines and antidepressants on the risk of death in patients with dementia initiating antipsychotic drug treatment.

METHODS: Nationwide registry data on all incident dementia cases among individuals aged 65 years and older in Denmark between 2009 and 2013 for which antipsychotic treatment was initiated were used. The 180-day mortality was evaluated by crude and adjusted hazard ratios (HRs, including adjustment for somatic and psychiatric comorbidity, other prescription drugs, nursing home residency, and time since diagnosis), comparing periods of antipsychotic treatment with periods of concomitant treatment with benzodiazepines or antidepressants.

RESULTS: Among 41,494 incident dementia cases, antipsychotic treatment was initiated for 10,291 (24.8%). After 3,140 people were excluded due to recent antipsychotic drug use or hospitalization, 7,151 people were included in the analysis. The total follow-up time during current antipsychotic treatment was 1,146 person-years, and 831 died during antipsychotic treatment. Compared with antipsychotic treatment alone, the risk of death increased during antipsychotic treatment in combination with benzodiazepines (adjusted HR = 2.19; 95% CI, 1.83-2.63), while there was a decreased risk of death during antipsychotic treatment in combination with antidepressants (adjusted HR = 0.61; 95% CI, 0.50-0.74).

CONCLUSIONS: The diverse impact of concomitant use of benzodiazepines and antidepressants on mortality may be due to a direct drug-related effect. Alternatively, the findings could reflect differential mortality associated with different indications for therapy. Although the results cannot prove causality, and there may be residual confounding, clinicians should be cautious when considering the combination of antipsychotics and benzodiazepines in patients with dementia.

OriginalsprogEngelsk
TidsskriftThe Journal of Clinical Psychiatry
Vol/bind81
Udgave nummer4
Sider (fra-til)12828
ISSN0160-6689
DOI
StatusUdgivet - 2 jun. 2020

Bibliografisk note

© Copyright 2020 Physicians Postgraduate Press, Inc.

ID: 61245700